CD274 and lung cancer: The efficacy of PD‐1/PD‐L1 inhibitor monotherapy in the primary treatment of stage IV non‐small cell lung cancer in patients at PS2 is currently unclear, as the KEYNOTE‐024 and IMpower110 trials enrolled only patients at PS0–1 as eligibility criteria.13, 14